(Press Release) Advent International’s Grupo Biotoscana (GBT), a biopharmaceutical company in Latin America, announced it has entered into a supply, distribution and license agreement with Basilea Pharmaceutical International for two pharmaceutical products in 19 Latin American countries including Brazil, Mexico, Argentina and Colombia.

MONTEVIDEO – September 13, 2016 – Grupo Biotoscana SL (GBT), a leading biopharmaceutical company in Latin America, announced today that it has entered into a supply, distribution and license agreement with Basilea Pharmaceutica International Ltd. (Basilea) for Basilea’s antifungal CRESEMBA® (isavuconazole) and Basilea’s antibiotic Zevtera® (ceftobiprole) in 19 countries in Latin America including Brazil, Mexico, Argentina and Colombia.

GBT, which is majority-owned by private equity firm Advent International, has operations in 10 Latin American countries, including high-growth geographies such as Argentina, Brazil, Colombia, Chile, Mexico Ecuador and Peru. The company focuses on fast-growing market segments such as specialty care, rare diseases and biopharmaceuticals.
Under the terms of the agreement, GBT holds an exclusive license to commercialize isavuconazole and ceftobiprole in Latin America. GBT will be responsible for marketing authorization applications, market access, commercialization and distribution of isavuconazole and ceftobiprole in the countries covered by the agreement.

Mariano García-Valiño, GBT’s CEO, stated: “We are very pleased to initiate a partnership with global anti-infective leader Basilea and to bring to Latin America isavuconazole and ceftobiprole, two innovative anti-infective molecules that could provide doctors and patients with novel treatment options for addressing the medical problem of increasing resistance in the areas of fungal and bacterial infections”.